Thalys Medical Technology Group Inc. (603716.SS)
CNY 10.69
(3.89%)
CNY 10.69
(3.89%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2 Billion CNY | -13.1% |
| 2022 | 2.3 Billion CNY | -11.19% |
| 2021 | 2.59 Billion CNY | 22.3% |
| 2020 | 2.12 Billion CNY | 16.1% |
| 2019 | 1.83 Billion CNY | 38.96% |
| 2018 | 1.31 Billion CNY | 43.12% |
| 2017 | 920.51 Million CNY | 46.74% |
| 2016 | 627.32 Million CNY | 18.44% |
| 2015 | 529.65 Million CNY | 19.01% |
| 2014 | 445.04 Million CNY | 13.48% |
| 2013 | 392.18 Million CNY | 38.5% |
| 2012 | 283.16 Million CNY | 46.16% |
| 2011 | 193.73 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 442.66 Million CNY | -9.4% |
| 2024 Q1 | 485.12 Million CNY | 1.78% |
| 2024 Q2 | 488.58 Million CNY | 0.71% |
| 2023 Q3 | 518.61 Million CNY | -8.5% |
| 2023 FY | 2 Billion CNY | -13.1% |
| 2023 Q1 | 444.06 Million CNY | -18.69% |
| 2023 Q2 | 566.79 Million CNY | 27.64% |
| 2023 Q4 | 476.65 Million CNY | -8.09% |
| 2022 Q2 | 571.01 Million CNY | -1.36% |
| 2022 Q1 | 578.88 Million CNY | -25.17% |
| 2022 FY | 2.3 Billion CNY | -11.19% |
| 2022 Q4 | 546.13 Million CNY | -10.85% |
| 2022 Q3 | 612.59 Million CNY | 7.28% |
| 2021 Q2 | 680.97 Million CNY | 31.76% |
| 2021 Q3 | 628.18 Million CNY | -7.75% |
| 2021 Q1 | 516.81 Million CNY | -32.77% |
| 2021 FY | 2.59 Billion CNY | 22.3% |
| 2021 Q4 | 773.57 Million CNY | 23.14% |
| 2020 Q2 | 490.17 Million CNY | 74.15% |
| 2020 Q1 | 281.47 Million CNY | -45.99% |
| 2020 FY | 2.12 Billion CNY | 16.1% |
| 2020 Q4 | 768.73 Million CNY | 31.39% |
| 2020 Q3 | 585.09 Million CNY | 19.36% |
| 2019 Q2 | 481.71 Million CNY | 33.84% |
| 2019 FY | 1.83 Billion CNY | 38.96% |
| 2019 Q3 | 467.99 Million CNY | -2.85% |
| 2019 Q4 | 521.12 Million CNY | 11.35% |
| 2019 Q1 | 359.93 Million CNY | -7.63% |
| 2018 Q3 | 353.28 Million CNY | 12.35% |
| 2018 Q2 | 314.44 Million CNY | 20.92% |
| 2018 Q1 | 260.05 Million CNY | -14.2% |
| 2018 FY | 1.31 Billion CNY | 43.12% |
| 2018 Q4 | 389.66 Million CNY | 10.3% |
| 2017 Q4 | 303.08 Million CNY | 17.85% |
| 2017 Q3 | 257.16 Million CNY | 30.2% |
| 2017 Q2 | 197.51 Million CNY | 21.35% |
| 2017 Q1 | 162.75 Million CNY | -3.88% |
| 2017 FY | 920.51 Million CNY | 46.74% |
| 2016 Q3 | 164.03 Million CNY | 5.32% |
| 2016 FY | 627.32 Million CNY | 18.44% |
| 2016 Q4 | 169.31 Million CNY | 3.22% |
| 2016 Q2 | 155.75 Million CNY | 12.69% |
| 2016 Q1 | 138.21 Million CNY | -2.44% |
| 2015 Q4 | 141.67 Million CNY | 1.59% |
| 2015 FY | 529.65 Million CNY | 19.01% |
| 2015 Q3 | 139.46 Million CNY | 0.0% |
| 2014 FY | 445.04 Million CNY | 13.48% |
| 2013 FY | 392.18 Million CNY | 38.5% |
| 2012 FY | 283.16 Million CNY | 46.16% |
| 2011 FY | 193.73 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 9.14 Billion CNY | 78.069% |
| Joinn Laboratories(China)Co.,Ltd. | 2.37 Billion CNY | 15.584% |
| WuXi AppTec Co., Ltd. | 40.04 Billion CNY | 94.99% |
| Autobio Diagnostics Co., Ltd. | 4.44 Billion CNY | 54.854% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 8.53 Billion CNY | 76.508% |
| Chemclin Diagnostics Co., Ltd. | 445.34 Million CNY | -350.472% |